» Articles » PMID: 11014954

Pure Versus Complicated Vulvar Vestibulitis: a Randomized Trial of Fluconazole Treatment

Overview
Date 2000 Oct 3
PMID 11014954
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the effectiveness of a 6-month treatment consisting of a weekly oral dose of 150 mg fluconazole for women with vestibulitis, and to explore the causes of treatment failure.

Methods: Forty women with vestibulitis were randomized to either of two treatment groups. One group received a 6-month low oxalate diet with calcium citrate complement, as a placebo, and the second group the same diet and calcium citrate with the addition of a weekly oral tablet of 150 mg fluconazole. The women were examined 3 months after completing treatment, for response to therapy.

Results: The addition of intensive 6-month fluconazole treatment did not lead to an outcome better than that attained by maintaining a low oxalate diet with calcium citrate supplementation. The satisfactory response rate was 15 and 30%, respectively. The presence of 'complicated vestibulitis', candidiasis concomitant with vestibulitis, decreases the satisfactory response rate regardless of the type of treatment administered (odds ratio 19.9, 95% CI 1.6, 250).

Conclusion: Prolonged oral fluconazole is an ineffective treatment of vestibulitis, whether pure or complicated by concomitant vulvovaginal candidiasis. The coexistence of candidiasis and vestibulitis - complicated vestibulitis - might represent a subset of vestibulitis that is resistant to the currently available medical therapy.

Citing Articles

Localized provoked vulvodynia as an immune-mediated inflammatory disease: rationale for a new line of research.

Paavonen J, Brunham R Front Cell Infect Microbiol. 2025; 14:1505845.

PMID: 39742333 PMC: 11685093. DOI: 10.3389/fcimb.2024.1505845.


Exploring Localized Provoked Vulvodynia: Insights from Animal Model Research.

Nakhleh-Francis Y, Awad-Igbaria Y, Sakas R, Bang S, Abu-Ata S, Palzur E Int J Mol Sci. 2024; 25(8).

PMID: 38673846 PMC: 11050705. DOI: 10.3390/ijms25084261.


Recruitment methods in a clinical trial of provoked vulvodynia: Predictors of enrollment.

Bachour C, Bachmann G, Foster D, Wan J, Rawlinson L, Brown C Clin Trials. 2016; 14(1):103-108.

PMID: 27488223 PMC: 5290291. DOI: 10.1177/1740774516663461.


A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation.

Falsetta M, Foster D, Bonham A, Phipps R BJOG. 2016; 124(2):210-218.

PMID: 27312009 PMC: 5164873. DOI: 10.1111/1471-0528.14157.


Etiology, diagnosis, and clinical management of vulvodynia.

Sadownik L Int J Womens Health. 2014; 6:437-49.

PMID: 24833921 PMC: 4014358. DOI: 10.2147/IJWH.S37660.